Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has earned a consensus rating of “Hold” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $2.32.
Separately, StockNews.com initiated coverage on shares of Cara Therapeutics in a report on Sunday. They set a “sell” rating on the stock.
Get Our Latest Stock Report on CARA
Cara Therapeutics Stock Performance
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last issued its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. As a group, equities research analysts forecast that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its position in Cara Therapeutics, Inc. (NASDAQ:CARA – Free Report) by 6.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after purchasing an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned about 3.54% of Cara Therapeutics worth $499,000 at the end of the most recent quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
See Also
- Five stocks we like better than Cara Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- 3 Monster Growth Stocks to Buy Now
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- When to Sell a Stock for Profit or Loss
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.